Peer-reviewed article
Clinical Evidence and Safety Profile of Emicizumab for the Management of Children with Hemophilia A
Sandra Le Quellec ·
Summary
Written by AI, not yet AICS's view · claude-haiku-4-5-20251001This is a clinical review of emicizumab, a drug treatment for hemophilia A in children. The document summarizes evidence from trials showing the drug reduces bleeding and is generally well tolerated, with benefits for quality of life. However, it notes that long-term safety data in very young children remains limited and calls for more research.
Key points
- Emicizumab prophylaxis significantly reduced bleeding rates in children and adolescents with hemophilia A compared to previous treatments
- The drug was generally well tolerated in clinical trials and case series
- Subcutaneous administration provided beneficial effects on health-related quality of life and reduced disease burden for patients and caregivers
- Limited data are currently available on use in children, particularly in very young and previously untreated patients
- Additional prospective studies are needed to evaluate long-term safety in very young patients
Limitations
This is a review article synthesizing limited existing data rather than primary research. It does not provide detailed information on study populations, trial designs, or specific outcome measurements that would be needed to assess the strength of evidence.
Abstract
Emicizumab is a bispecific, humanized, monoclonal antibody mimicking the factor (F) VIII cofactor activity in mediating the generation of FXa by FIXa in patients with hemophilia A (HA). This subcutaneous non-factor agent has been recently extensively approved for the prophylaxis of patients of HA patients with and without FVIII-inhibitors of all ages, although few data are currently available in children. In Phase 3 clinical trials and case series, emicizumab prophylaxis significantly reduced bleeding rates compared to previous treatment in HA adolescents and children with or without FVIII-inhibitors and was generally well tolerated. In addition, subcutaneous administration of emicizumab provided beneficial effects on health-related quality of life, and lessened the burden of the disease in HA patients as well as in their caregivers. However, additional prospective studies are required to evaluate the long-term safety of emicizumab prophylaxis in very young patients, including previously untreated patients. The aim of this paper was to review the limited data available on the use of emicizumab prophylaxis in children and to highlight the need for further studies to address remaining concerns.